Investigational Site Number :1240001

Toronto, Ontario M5T 3A9

1 studies enrolling now · 10 studies all time

What they study most

Asthma, Chronic Obstructive Pulmonary Disease, Cold Urticaria, Hemophilia A, Malignant Solid Tumor, Neoplasm, Neurodermatitis, Plasma Cell Myeloma Recurrent, Thrombotic Thrombocytopenic Purpura

Studies at this site

• Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype — Recruiting now
• Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A — Running, not enrolling
• Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma — Running, not enrolling
• Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura — Completed
• SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM — Running, not enrolling
• Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2) — Completed
• Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A — Completed
• Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS) — Completed
• A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors — Completed
• Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies — Stopped early